Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1981 Nov;68(5):1149–1157. doi: 10.1172/JCI110359

Hepatic and renal metabolism of somatostatin-like immunoreactivity. Simultaneous assessment in the dog.

K S Polonsky, J B Jaspan, M Berelowitz, D S Emmanouel, J Dhorajiwala
PMCID: PMC370908  PMID: 6117570

Abstract

The hepatic and renal metabolism of somatostatin-like immunoreactivity (SLI) was assessed simultaneously in an in vivo dog model. The hepatic extraction of this peptide was 29.4 +/- 2.3% and was similar for endogenous and infused exogenous SLI. The renal extraction was 62.3 +/- 5%. The renal clearance of SLI was significantly greater than that of inulin indicating that the peptide is handled by peritubular uptake from postglomerular blood in addition to glomerular filtration. In both organs SLI extraction was not saturable even at arterial concentrations in excess of 100 times physiological range. The overall metabolic clearance rate of SLI was 19.7 +/- 1.6 ml/kg per minute of which 32.7 +/- 4.6% was contributed by hepatic and 37 +/- 4.9% by renal uptake mechanisms. The plasma half disappearance time of exogenously infused SLI was 1.9 +/- 0.3 min. The studies indicate that in the dog, the liver and kidney are both major sites of SLI metabolism, together accounting for 70.0 +/- 8.7% of the metabolic clearance of the peptide.

Full text

PDF
1149

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arimura A., Sato H., Dupont A., Nishi N., Schally A. V. Somatostatin: abundance of immunoreactive hormone in rat stomach and pancreas. Science. 1975 Sep 19;189(4207):1007–1009. doi: 10.1126/science.56779. [DOI] [PubMed] [Google Scholar]
  2. Berelowitz M., Cibelius M., Szabo M., Frohman L. A., Epstein S., Bell N. H. Somatostatin-like immunoreactivity in transplantable medullary carcinoma of rat thyroid: partial chromatographic and biological characterization. Endocrinology. 1980 Nov;107(5):1418–1424. doi: 10.1210/endo-107-5-1418. [DOI] [PubMed] [Google Scholar]
  3. Berelowitz M., Kronheim S., Pimstone B., Shapiro B. Somatostatin-like immunoreactivity in rat blood. Characterization, regional differences, and responses to oral and intravenous glucose. J Clin Invest. 1978 May;61(5):1410–1414. doi: 10.1172/JCI109059. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bloom S. R., Mortimer C. H., Thorner M. O., Besser G. M., Hall R., Gomez-Pan A., Roy V. M., Russell R. C., Coy D. H., Kastin A. J. Inhibition of gastrin and gastric-acid secretion by growth-hormone release-inhibiting hormone. Lancet. 1974 Nov 9;2(7889):1106–1109. doi: 10.1016/s0140-6736(74)90869-1. [DOI] [PubMed] [Google Scholar]
  5. Brazeau P., Vale W., Burgus R., Ling N., Butcher M., Rivier J., Guillemin R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science. 1973 Jan 5;179(4068):77–79. doi: 10.1126/science.179.4068.77. [DOI] [PubMed] [Google Scholar]
  6. Chamberlain M. J., Stimmler L. The renal handling of insulin. J Clin Invest. 1967 Jun;46(6):911–919. doi: 10.1172/JCI105597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cherrington A. D., Chiasson J. L., Liljenquist J. E., Jennings A. S., Keller U., Lacy W. W. The role of insulin and glucagon in the regulation of basal glucose production in the postabsorptive dog. J Clin Invest. 1976 Dec;58(6):1407–1418. doi: 10.1172/JCI108596. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Conlon J. M., Srikant C. B., Ipp E., Schusdziarra V., Vale W., Unger R. H. Properties of endogenous somatostatin-like immunoreactivity and synthetic somatostatin in dog plasma. J Clin Invest. 1978 Dec;62(6):1187–1193. doi: 10.1172/JCI109238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Emmanouel D. S., Jaspan J. B., Rubenstein A. H., Huen A. H., Fink E., Katz A. I. Glucagon metabolism in the rat. J Clin Invest. 1978 Jul;62(1):6–13. doi: 10.1172/JCI109114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gerich J. E., Lorenzi M., Bier D. M., Schneider V., Tsalikian E., Karam J. H., Forsham P. H. Prevention of human diabetic ketoacidosis by somatostatin. Evidence for an essential role of glucagon. N Engl J Med. 1975 May 8;292(19):985–989. doi: 10.1056/NEJM197505082921901. [DOI] [PubMed] [Google Scholar]
  11. Harding P. E., Bloom G., Field J. B. Effect of infusion of insulin into portal vein on hepatic extraction of insulin in anesthetized dogs. Am J Physiol. 1975 May;228(5):1580–1588. doi: 10.1152/ajplegacy.1975.228.5.1580. [DOI] [PubMed] [Google Scholar]
  12. Hruska K. A., Blondin J., Bass R., Santiago J., Thomas L., Altsheler P., Martin K., Klahr S. Effect of intact parathyroid hormone on hepatic glucose release in the dog. J Clin Invest. 1979 Oct;64(4):1016–1023. doi: 10.1172/JCI109538. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hökfelt T., Elfvin L. G., Elde R., Schultzberg M., Goldstein M., Luft R. Occurrence of somatostatin-like immunoreactivity in some peripheral sympathetic noradrenergic neurons. Proc Natl Acad Sci U S A. 1977 Aug;74(8):3587–3591. doi: 10.1073/pnas.74.8.3587. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Jaspan J. B., Polonsky K. S., Lewis M., Pensler J., Pugh W., Moossa A. R., Rubenstein A. H. Hepatic metabolism of glucagon in the dog: contribution of the liver to overall metabolic disposal of glucagon. Am J Physiol. 1981 Mar;240(3):E233–E244. doi: 10.1152/ajpendo.1981.240.3.E233. [DOI] [PubMed] [Google Scholar]
  15. Jaspan J. B., Polonsky K. S., Röjdmark S., Ishida T., Field J. B., Rubenstein A. H. Hepatic extraction of plasma immunoreactive glucagon components. Predilection for 3500-dalton glucagon metabolism by the liver. Diabetes. 1981 Sep;30(9):767–772. doi: 10.2337/diab.30.9.767. [DOI] [PubMed] [Google Scholar]
  16. Kayasseh L., Gyr K., Keller U., Stalder G. A., Wall M. Somatostatin and cimetidine in peptic-ulcer haemorrhage. A randomised controlled trial. Lancet. 1980 Apr 19;1(8173):844–846. doi: 10.1016/s0140-6736(80)91352-5. [DOI] [PubMed] [Google Scholar]
  17. Koerker D. J., Ruch W., Chideckel E., Palmer J., Goodner C. J., Ensinck J., Gale C. C. Somatostatin: hypothalamic inhibitor of the endocrine pancreas. Science. 1974 Apr 26;184(4135):482–484. doi: 10.1126/science.184.4135.482. [DOI] [PubMed] [Google Scholar]
  18. Kronheim S., Berelowitz M., Pimstone B. L. The characterization of growth hormone release inhibiting hormone-like immunoreactivity in normal urine. Clin Endocrinol (Oxf) 1977 Oct;7(4):343–347. doi: 10.1111/j.1365-2265.1977.tb01332.x. [DOI] [PubMed] [Google Scholar]
  19. Kronheim S., Berelowitz M., Pimstone B. L. The characterization of somatostatin-like immunoreactivity in human serum. Diabetes. 1978 May;27(5):523–529. doi: 10.2337/diab.27.5.523. [DOI] [PubMed] [Google Scholar]
  20. Lundqvist G., Gustavsson S., Elde R., Arimura A. A radioimmunoabsorbent assay for plasma somatostatin. Clin Chim Acta. 1980 Feb 28;101(2-3):183–191. doi: 10.1016/0009-8981(80)90243-0. [DOI] [PubMed] [Google Scholar]
  21. MORTIMORE G. E., TIETZE F., STETTEN D., Jr Metabolism of insulin-I 131; studies in isolated, perfused rat liver and hindlimb preparations. Diabetes. 1959 Jul-Aug;8(4):307–314. doi: 10.2337/diab.8.4.307. [DOI] [PubMed] [Google Scholar]
  22. Oliver J. R., Wagle S. R. Studies on the inhibition of insulin release, glycogenolysis and gluconeogenesis by somatostatin in the rat islets of langerhans and isolated hepatocytes. Biochem Biophys Res Commun. 1975 Feb 3;62(3):772–777. doi: 10.1016/0006-291x(75)90466-0. [DOI] [PubMed] [Google Scholar]
  23. Patel Y. C., Wheatley T., Fitz-Patrick D., Brock G. A sensitive radioimmunoassay for immunoreactive somatostatin in extracted plasma: measurement and characterization of portal and peripheral plasma in the rat. Endocrinology. 1980 Jul;107(1):306–313. doi: 10.1210/endo-107-1-306. [DOI] [PubMed] [Google Scholar]
  24. Rabkin R., Kitabchi A. E. Factors influencing the handling of insulin by the isolated rat kidney. J Clin Invest. 1978 Jul;62(1):169–175. doi: 10.1172/JCI109102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Rabkin R., Rubenstein A. H., Colwell J. A. Glomerular filtration and proximal tubular absorption of insulin 125 I. Am J Physiol. 1972 Nov;223(5):1093–1096. doi: 10.1152/ajplegacy.1972.223.5.1093. [DOI] [PubMed] [Google Scholar]
  26. Raptis S., Schlegel W., Lehmann E., Dollinger H. C., Zoupas C. Effects of somatostatin on the exocrine pancreas and the release of duodenal hormones. Metabolism. 1978 Sep;27(9 Suppl 1):1321–1328. doi: 10.1016/0026-0495(78)90066-5. [DOI] [PubMed] [Google Scholar]
  27. Rubenstein A. H., Pottenger L. A., Mako M., Getz G. S., Steiner D. F. The metabolism of proinsulin and insulin by the liver. J Clin Invest. 1972 Apr;51(4):912–921. doi: 10.1172/JCI106886. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Sacks H., Terry L. C. Clearance of immunoreactive somatostatin by perfused rat liver. J Clin Invest. 1981 Feb;67(2):419–429. doi: 10.1172/JCI110050. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Schally A. V., Dupont A., Arimura A., Redding T. W., Nishi N., Linthicum G. L., Schlesinger D. H. Isolation and structure of somatostatin from porcine hypothalami. Biochemistry. 1976 Feb 10;15(3):509–514. doi: 10.1021/bi00648a009. [DOI] [PubMed] [Google Scholar]
  30. Schusdziarra V., Harris V., Conlon J. M., Arimura A., Unger R. Pancreatic and gastric somatostatin release in response to intragastric and intraduodenal nutrients and HCl in the dog. J Clin Invest. 1978 Sep;62(3):509–518. doi: 10.1172/JCI109154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Sönksen P. H., Tompkins C. V., Srivastava M. C., Nabarro J. D. A comparative study on the metabolism of human insulin and porcine proinsulin in man. Clin Sci Mol Med. 1973 Nov;45(5):633–654. doi: 10.1042/cs0450633. [DOI] [PubMed] [Google Scholar]
  32. Terris S., Steiner D. F. Retention and degradation of 125I-insulin by perfused livers from diabetic rats. J Clin Invest. 1976 Apr;57(4):885–896. doi: 10.1172/JCI108365. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. UNGER R. H., EISENTRAUT A. M., McCALL M. S., MADISON L. L. Glucagon antibodies and an immunoassay for glucagon. J Clin Invest. 1961 Jul;40:1280–1289. doi: 10.1172/JCI104357. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Utsumi M., Makimura H., Ishihara K., Morita S., Baba S. Determination of immunoreactive somatostatin in rat plasma and responses to arginine, glucose and glucagon infusion. Diabetologia. 1979 Nov;17(5):319–323. doi: 10.1007/BF01235888. [DOI] [PubMed] [Google Scholar]
  35. Vinik A. I., Levitt N. S., Pimstone B. L., Wagner L. Peripheral plasma somatostatin-like immunoreactive responses to insulin hypoglycemia and a mixed meal in healthy subjects and in noninsulin-dependent maturity-onset diabetics. J Clin Endocrinol Metab. 1981 Feb;52(2):330–337. doi: 10.1210/jcem-52-2-330. [DOI] [PubMed] [Google Scholar]
  36. Yamada T., Marshak D., Basinger S., Walsh J., Morley J., Stell W. Somatostatin-like immunoreactivity in the retina. Proc Natl Acad Sci U S A. 1980 Mar;77(3):1691–1695. doi: 10.1073/pnas.77.3.1691. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES